Sugi Predict

Sugi Predict / Compounds / SCHEMBL264717

SCHEMBL264717

SCHEMBL264717

Cc1cnc(Nc2ccc(CN3CCOCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 16/20 0.69
▸ JAK2 O60674 6/20 0.69
▸ JAK1 P23458 5/20 0.69
▸ JAK3 P52333 3/20 0.69
▸ FLT3 P36888 3/20 0.69
▸ RET P07949 2/20 0.69
▸ WEE1 P30291 2/20 0.69
▸ BRDT Q58F21 2/20 0.69
▸ ALK Q9UM73 2/20 0.69
▸ BUB1B O60566 1/20 0.69
▸ BRD2 P25440 1/20 0.69
▸ BRD3 Q15059 1/20 0.69
▸ TYK2 P29597 2/20 0.67
▸ BMPR1B O00238 1/20 0.67
▸ PLK4 O00444 1/20 0.67
▸ STK25 O00506 1/20 0.67
▸ CIT O14578 1/20 0.67
▸ RIOK3 O14730 1/20 0.67
▸ CHEK1 O14757 1/20 0.67
▸ IKBKB O14920 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266638 0.94 BRD4 (0.65) BRD4JAK2JAK1JAK3FLT3
Hydrochloric Acid SCHEMBL264113 0.94 BRD4 (0.64) BRD4JAK2JAK1JAK3FLT3
SCHEMBL265608 0.91 BRD4 (0.78) BRD4JAK2JAK1JAK3FLT3
SCHEMBL264387 0.90 BRD4 (0.67) BRD4JAK2JAK1JAK3FLT3
SCHEMBL263665 0.88 BRD4 (0.84) BRD4JAK2JAK1JAK3FLT3
SCHEMBL14536084 0.88 NTRK1 (0.62) JAK2JAK1JAK3FLT3RET
SCHEMBL25383630 0.87 BRD4 (0.81) BRD4JAK2JAK1JAK3FLT3
SCHEMBL30565237 0.87 BRD4 (0.81) BRD4JAK2JAK1JAK3FLT3
SCHEMBL13865305 0.86 BRD4 (0.72) BRD4JAK2JAK1JAK3FLT3
SCHEMBL25383250 0.86 BRD4 (0.69) BRD4JAK2JAK1JAK3FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107250-A1 METHODS AND SYSTEMS FOR PROFILING FATTY LIVER DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-21 — — WO claimed
CN-119856057-A Ataxin-sensitive lipid markers for monitoring ataxin replacement therapy 拉利玛生物医药公司 2025-04-18 — — CN claimed
EP-4522994-A1 FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY Larimar Therapeutics, Inc. (US) 2025-03-19 — — EP claimed
WO-2023220657-A9 FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY LARIMAR THERAPEUTICS, INC. (US) 2024-10-24 — — WO claimed
US-20240142476-A1 FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY LARIMAR THERAPEUTICS, INC. 2024-05-02 — — US claimed
CN-117448170-A Penicillium TG46 and application thereof in preparation of patulin 云南大学 2024-01-26 — — CN claimed
WO-2023220657-A1 FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY LARIMAR THERAPEUTICS, INC. (US) 2023-11-16 — — WO claimed
US-20260148698-A1 DISPLAY DEVICE SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) 2026-05-28 — — US disclosed
WO-2026107250-A1 METHODS AND SYSTEMS FOR PROFILING FATTY LIVER DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-21 — — WO disclosed
US-20260127989-A1 DISPLAY DEVICE AND ANALYSIS METHOD SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) 2026-05-07 — — US disclosed
US-20250166821-A1 METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE SAGIMET BIOSCIENCES INC. 2025-05-22 — — US disclosed
WO-2025100217-A1 DISPLAY DEVICE ソニーセミコンダクタソリューションズ株式会社 2025-05-15 — — WO disclosed
WO-2025100106-A1 SIGNAL PROCESSING DEVICE, DISPLAY SYSTEM, AND ELECTRONIC APPARATUS ソニーグループ株式会社 2025-05-15 — — WO disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
WO-2007053452-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 BRD4 142/4885JAK2 1/4885JAK1 4/4885
US-20260127989-A1 DISPLAY DEVICE AND ANALYSIS METHOD OCIAD1, OCIAD2, DSP BRD4 3027/4885JAK2 1921/4885JAK1 1088/4885
US-20260148698-A1 DISPLAY DEVICE RAMP1, RAMP2, RAMP3 BRD4 2134/4885JAK2 1339/4885JAK1 1071/4885
US-20250166821-A1 METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE ACACB, ACACA, ACLY BRD4 1404/4885JAK2 4359/4885JAK1 4234/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 BRD4 142/4885JAK2 1/4885JAK1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.